Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth ...

The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Vertex has built an empire in cystic fibrosis ... projecting an 8.2% jump in sales for 2025 as new products gain traction.

The healthcare sector has struggled to deliver worthwhile returns for investors since 2021, weighed down by several headwinds. Rising interest rates, challenges in the U.S. healthcare system, and the ...

Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed ... projecting an 8.2% jump in sales for 2025 as new products gain traction. The balance sheet tells an equally ...

Wall Street sees plenty of growth ahead, projecting an 8.2% jump in sales for 2025 as new products gain traction ... dollar markets, Vertex offers a compelling mix of stability and upside potential.